Primary brain tumors are a major cause of cancer mortality in the United States. Therapy for gliomas, the most common type of primary brain tumors, remains suboptimal.
Introduction
Brain tumors are a major cause of cancer mortality in children and adults in the United States (1) . Current treatment for gliomas, the most common type of primary brain tumors, remains suboptimal and the promise for improved therapies rests largely on a better understanding of the underlying biology and genetics of these tumors. The majority of genomic alterations described in gliomas (2, 3) have been found in the more common epithelial tumors (EGFR, CDKN2A, TP53, RB1, and PTEN). Targeted therapies (e.g., erlotinib) directed to these ubiquitous cancer-associated targets, such as the epithelial growth factor receptor (EGFR), have unfortunately met with limited success (4, 5) , underlining the need for the identification of glioma-specific genomic alterations.
In an attempt to solve this problem, we have created a National Cancer Institute-funded national, multi-institutional project called the Glioma Molecular Diagnostic Initiative, the goal of which is to collect and molecularly characterize (at RNA, DNA, and protein levels) more than 1,000 gliomas with the associated corollary clinical data. As part of the first phase of Glioma Molecular Diagnostic Initiative, we analyzed 178 tumors (6) for genomic alterations using Affymetrix 100K single-nucleotide polymorphism (SNP) arrays (7) . This assay relies on the detection of the specific genotype by hybridization of enzyme-modified, PCR-amplified genomic DNA to 40 probes specific for a single SNP. By using both allelic calls and signal intensity, such arrays can be successfully used for genomic survey studies in nonfamilial diseases such as cancer. Although our SNP-based genomic survey gave us a significantly higher resolution survey of genomic alterations found in gliomas compared with previously done traditional comparative genomic hybridization-based studies, the SNP arrays still only allow the identification of relatively large areas of alteration (>100 kbp). The list of genes found in these regions can be large, even when restricting the genes of interest to those that are closer to the peak of the alteration histogram. Not only are genes important for the tumorigenic process (''driver'' genes) found within these large SNP array-determined altered chromosomal regions but neighboring genes that have no role in tumorigenesis (''passenger genes'') may also be found. Thus, the determination of which of the many genes identified through such analysis are the relevant driver genes is a significant bioinformatic challenge.
Lists of genes potentially important for tumorigenesis have also been generated through mRNA expression profiling. Although potentially useful as a biomarker for the current transcriptional state of a given tumor, the mRNA expression profile for most genes merely reflects normal cellular processes rather than those intrinsic to the initiation and/or propagation of the tumorigenic state. The statistical probability of any one of these genes with altered expression being important in tumorigenesis is relatively low. Thus, we have attempted to address the limitations of identifying tumorrelevant genes using a single platform analysis by combining the SNP and gene expression analyses to find genes that behave concordantly between the two different platforms (i.e., the mRNA of an amplified gene is also overexpressed). This approach, for instance, allows one to quickly disregard genes that have copy number alteration (CNA) but whose mRNA expression profile is not significantly different from normal tissue. Therefore, to enrich for genetic alterations that may have true biological relevance, we have correlated the levels of mRNA expression of each gene to the calculated copy numbers of the genomic area associated with the gene. We believe that this approach will increase the likelihood of identifying genes that might be the primary target of a specific tumor-associated genomic event and, thus, a good candidate for further study.
Additionally, we also identified some genes whose correlation with the genomic copy numbers may be partially governed by epigenetic modulation. To this end, we specifically looked for reporters that had unusually low expression compared with nontumor samples and were located in the areas with loss of heterozygosity (LOH) secondary to either a deletion (1n) or a recombination event (2n) to remove the remaining active allele. Several of these identified candidate genes were validated with realtime PCR and methylation sequencing assays. We believe that this refined list of structurally and functionally altered genomic elements will provide a strong basis for the discovery of genes involved in the induction, propagation, and/or maintenance of gliomas and may expand the list of potential glioma-specific therapeutic targets.
Materials and Methods
Samples. One hundred forty gliomas from the Hermelin Brain Tumor Center, Departments of Neurology and Neurosurgery, at the Henry Ford Hospital were analyzed in this study. The samples were provided as snap frozen sections of areas immediately adjacent to the region used for the histopathologic diagnosis. This set included 67 glioblastomas, 27 astrocytomas, 38 oligodendrogliomas, and 8 oligoastrocytomas (mixed) tumors. Fifteen nontumor samples (temporal lobe resection of epileptic patients) were analyzed concurrently to provide a baseline for the mRNA expression values.
DNA extraction and hybridization. DNA from the assayed samples was extracted and hybridized to the Affymetrix 100K SNP chips (8) using the methods previously reported (6) .
RNA extraction and hybridization. Approximately 50 to 100 mg of tissue from each tumor were used for total RNA using the Trizol reagent (Invitrogen) following the manufacturer's instructions. The quality of RNA obtained was verified with the Bioanalyzer System (ref. 9; Agilent Technologies) using the RNA Pico Chips. Six micrograms of RNA were processed for hybridization on the Genechip Human Genome U133 Plus 2.0 Expression arrays (Affymetrix, Inc.; ref. 10), which contains >54,000 probe sets associated with >47,000 transcripts and variants, including 38,500 well-characterized human genes. The processing was done according to the manufacturer's recommendations. After hybridization, the chips were processed using fluidics station 450, high-resolution microarray scanner 3000, and GCOS workstation version 1.3. Expression levels were determined by GCOS version 1.3, which uses the MAS5 algorithm. Expression values were scaled to a mean of 500, and only samples with a scaling factor <5, present call rates >35%, and a GAPDH 3 ¶/5 ¶ ratio <3 were accepted for the analysis (11) . The gene expression CEL files were normalized using dChip (12) invariant method, and PM-MM difference model was used to obtain the expression values (log 2 ) for further analysis.
Copy number determination. Chromosome copy numbers were estimated as previously described (6) .
Expression-copy number correlation analysis. To correlate RNA expression with DNA copy number, each HG-U133_Plus_2 probe set was mapped against all the SNPs located in a window of 1 Mbp around the center of that probe set. To improve reliability, we filtered genomic alignments of mRNA probe sets using the following criteria: (a) Only probe sets of grades A and B (according to Affymetrix annotation), which fully or partially overlap with mRNA transcripts, were used. (b) We selected only probe sets associated with a RefSeq gene and with genomic alignments mapped to the same single gene. (c) If there were multiple alignments of the same probe set, they were checked to assess if they overlapped at least partially. (d) Sequence identity of genomic alignments had to exceed 80%. Using these parameters, 21,611 probe sets (representing 17,087 genes) were selected and used for further analysis. Additionally, probes whose variance of expression values (without outliers) for a particular probe set equals zero were excluded from analysis because the correlation coefficient cannot be estimated. The average copy number for those SNPs was calculated from the original CNAT copy numbers, and correlation coefficients and significance (P value) between that average and the mRNA expression value for the associated probe set were calculated using locally developed Matlab scripts. Positions of both expression and SNP probe sets were annotated using Affymetrix NetAffx annotation service Statistical analysis. Correlation coefficients and significance P values between averaged copy number and the mRNA expression value for an associated probe set with prior removal of outlying samples were calculated using Matlab. Samples were considered outliers for a particular probe set if its expression or copy number values differed from the mean by more than 3 SDs. Outliers were removed to reduce the detection of false positives because a significant outlier can produce a high correlation coefficient through its distance to the bulk of the samples, creating an artificial correlation line not seen if the outlying sample is removed.
To select probe sets with expression values in tumors showing LOH in the region lower than in the nontumor samples, standard two-sided t tests have been done. Probe sets with P < 0.05 and fold changes higher than twice the median expression of nontumor samples were used.
LOH analysis. LOH scores for each SNP were calculated as previously described (6) . To detect LOH for each expression probe set, LOH scores of all SNPs in a window of 1 Mbp around the center of probe set were averaged as described above for copy number. Samples were considered to have LOH in particular area, if corresponding mean LOH score was >6. Probe sets with >10% of LOH samples were selected for the analysis to concentrate on highly relevant genes.
CpG island estimation. Genomic coordinates of all RefSeq genes and all CpG islands (<200 bp) were extracted from UCSC Genome Browser (2004). The percentage of 5 ¶ CpG island genes were calculated for randomly selected gene sample of the same size as a number of genes in the tested gene set (271 unique genes). The process was repeated 10,000 times. Z-test P value was calculated.
Real-time reverse transcription-PCR. To confirm that the expression in samples or probe sets shows very low levels, mRNA expression levels were quantified by real-time RT PCR done on an ABI Prism 7900 sequence detection system (Applied Biosystems) as previously described (13) .
Methylation-specific sequencing. Promoter methylation in the 5 ¶ CpG island of two candidate genes (CXCL12 and PTER) was done in six tumor samples (HF0184, HF0627, HF0992, HF1057, HF1090, and HF01458) showing extremely low mRNA expression despite their gene dosage. One sample with copy number adequate expression (HF0329) was used as control. Bisulfite conversion of DNA samples was done using Active Motif MethylDetector kit (Active Motif) following the manufacturer's instructions. For amplification of the CpG islands, the following primers were used: PTER-PTERmeth300F1 (GAATTGTGGGTTTAGTAGGAAGAGT) and PTERmeth300B5 (CAAAACCAAACCCTAAATCTAAAAA) for the first PCR, and PTERmeth300F1 and PTERmeth300B1 (TAAAAAAAACTTAACA-CAACTACCC); CXCL12-CXCL12methF1 (TTGTTTTTGTGATAGGGTTT-TATTG) and CXCL12methB1 (ACTTTTCATTAATTCTCATTCAATTCC). PCR products were then subcloned using the TOPO TA Cloning Kit (Invitrogen) following the manufacturer's instructions. Ten to sixteen PCRverified clones were then sequenced using the vectors T3 and T7 priming sites.
Results
mRNA probe set mapping and copy number calculation. To correlate mRNA expression levels with genomic copy numbers, we first mapped every probe set on the Affymetrix Human U133 Plus 2 chip to the SNPs probes. The mapping strategy is represented in Fig. 1A .
Once the positions of the expression probe sets were curated (as described in Materials and Methods), we calculated the associated genomic copy number by averaging individual SNPs copy numbers in a window of a given size. Because, depending on window size, a number of probe sets may have no single SNP in a window (e.g., third probe set in Fig. 1A ), making them noninformative for the correlation analysis, we analyzed which window length would give us optimal coverage while removing most of the noise. Figure  1B illustrates this process for both SNP chip types. A window of 1 Mbp was selected as an acceptable compromise between resolution and number of removed probe sets (f900 probe sets, f3%), allowing us to investigate most of the selected probe sets without averaging through such a large genomic span that would render the platform resolution meaningless. To confirm the validity of this window, we analyzed the effect in probe set selection using two other window sizes (500 kB and 1.5 Mb; Supplementary Fig. S1 ). As seen in Supplementary Fig. S1A , the correlation in the distribution of probe sets among the three different window sizes is quite high, with coefficients >0.89. Moreover, the overlap in probe set identity found with the three conditions is quite high as shown by the Venn diagrams ( Supplementary Fig. S1B and C) . The distribution of probe sets by number of SNPs in a window of 1 Mbp for both array types is shown in Fig. 1C ; as can be seen, most probe sets will have copy number information from 10 to 15 SNPs effectively suppressing the effect of unreliable (outlier) data points.
Correlation of mRNA expression versus copy number. To determine the gene expression level-copy number relationship on a genomic scale, we calculated correlation coefficients between these two different values along the genome. To test the no-correlation hypothesis, we calculated the P values as the probability of getting a correlation as large as that observed by random chance, when the true correlation is zero. Both correlation coefficients and P values (for Xba chips) are represented in Supplementary Fig. S2A (center  and bottom plots) . The data clearly show that the majority of highly correlated probe sets are located in areas of common deletions or amplifications ( Supplementary Fig. S2A, top plot) , suggesting a nonrandom discovery. Plots for Hind chips are almost identical (data not shown). The use of both the Hind and Xba chips serves as an internal control for the accuracy of the analyses from each individual chip. Supplementary Fig. S2B shows high concordance between the Xba and Hind chip-derived correlation coefficients consistent with the robustness of the data.
To select highly correlated probes, we applied a threshold of F0.3 to correlation coefficients for both chips, corresponding to P < 1 Â 10 À4 . Although this threshold leads to a P value cutoff substantially more stringent than the traditional 0.001 value, we opted to minimize the number of false positives by adopting a Table 1, with complete lists shown in  Supplementary Tables S1 and S2. Our correlation coefficients ranged between À0.6 and 0.7, a number generally higher than that reported in previous studies (14, 15) . Not surprisingly, and as a good control for the accuracy of our methods, the gene with the highest correlation coefficient (0.74) in our analysis corresponds to XIST (X inactivation-specific transcript), a gene known to participate in the silencing of the second X chromosome in females and one that separates male and females into two clusters as we have previously shown (6). Other highly correlated genes were found on a variety of chromosomes including chromosomes 1, 7, 9, 10, 13, 14, 19, 20, and 22. Expression-copy number scatter plots of eight of those genes, both positively and negatively correlated, are shown in Fig. 2 .
Identification of epigenetically modulated genes. In accordance with the Knudson hypothesis, tumor suppressor genes (TSG) are often inactivated in a two-step process often involving a deletion of the first allele followed by mutational or epigenetic silencing of the remaining allele. To identify epigenetically modulated genes that could be potential TSG, we looked for mRNA probe sets that had substantially lower expression than expected by its genomic copy number, as compared with nontumor samples, and located within areas of LOH. We identified 3,353 Figure 2 . Scatterplot of several genes with both positive (top row ) and negative (bottom row) correlation coefficients between expression and copy number. Genes with many samples having amplification are grouped on the two left columns; genes with many samples having deletions, on the two right columns.
probe sets (2,001 unique genes) within areas of LOH in at least 10% of the samples. From these, 403 probe sets (305 unique genes) showed significantly lower expression (P < 0.05 and a >2-fold change from nontumor median expression) than nontumor samples (Supplementary Table S3 ). In some of these probe sets, we observed a binary separation of LOH samples into two groups, one with expression similar to nontumor samples and another with very low or no expression, as is the case of PTER and CXCL12 (Fig. 3) . These genes are different from the negatively correlated genes shown in Fig. 2 (bottom) because their correlation coefficient was positive, although at a significance level less than would be expected if expression from the single remaining allele was normal.
Validation of microarray determined mRNA levels. Due to the unreliability of assessing expression levels for any given gene using only microarray probe sets, we confirmed the expression level of some of our identified genes to rule out false positives (especially those that had lower expression level such as the 305 putative TSGs). To this end, we performed quantitative real-time reverse transcription-PCR (RT-PCR) on a variety of both low-and high-expressing genes (using f10 samples in each case) to do a correct correlation analysis. Six of such assays are plotted in Fig. 4A . As can be seen, the correlation between the microarray and RT-PCR measured values is striking (correlation coefficients of 0.92-0.69) given the often-cited deficiencies of the microarray system. These assays validate the expression values we generated with the Affymetrix chips, thus reducing the likelihood that our analysis has identified a significant number of false positive candidates.
Validation of epigenetic modulation targets. The discrepancy between the allelic copy number and the quantitative PCRconfirmed expression values gives credence to the argument that a number of the 305 identified target genes may be at least partially under epigenetic regulation. Since one of the most common epigenetic regulatory mechanisms involves the methylation of promoter region CpG islands, we investigated the methylation status of the upstream region of a number of these genes. Using the UCSC Genome Browser, we assessed that 80.7% of all the target genes had a CpG island (CpG >55%, at least 300 bp long), compared with 69.4% of genes in a random sample of 305 genes (Supplementary Fig. S3 ) in our data set, or 65.4% of all the genes in the Human Genome (16), giving us a Z-test P = 0. To directly show the presence of promoter region methylation, we selected two of the genes (CXCL12 and PTER) that were either clearly underexpressed or normally expressed (compared with normal tissue) in different glioma samples. As shown in Fig. 4B and C, tumors that had very low level expression of either CXCL12 or PTER had very high rates of CpG methylation in their respective promoters, whereas tumors that had normal expression levels had relatively low rates of CpG methylation consistent with methylation-mediated down-regulation of the nondeleted allele in low-expressing tumors.
Discussion
We recently reported our analysis of genomic alterations in 178 gliomas using the Affymetrix 100K SNP arrays (6) . Although this genomic survey allowed us to probe the glioma genome at a higher resolution than had previously been accomplished, thereby allowing us to identify new areas of CNAs, the areas identified were still substantially larger than 100 kbp. As such, the number of genes found in any given region of CNA is large, making the distinction between driver and passenger genes difficult. Likewise, genes identified solely by their expression profiles may be useful biomarkers for the disease state but have a statistically low probability of being at the root of the tumorigenic process. Therefore, to increase the chances of identifying genes most likely of biological relevance, we correlated the levels of mRNA expression with their calculated copy numbers. Through this methodologic approach, we enrich for candidate genes with a higher probability of being the primary targets of the oncogenic genomic alteration rather than being a bystander or passenger to the event.
Two prior studies attempted to similarly correlate chromosomal changes with gene expression in gliomas (14, 15) . Although these were important advances at the time, we believe that the present study significantly adds to the current state of knowledge in that the prior studies used lower-resolution comparative genomic hybridization, used a much fewer tumors, and restricted the gene expression analysis to a limited number of genes and/or regions of interest. Although both the SNP and gene expression microarray platforms we used cannot be considered as quantitative assays, the combination of both these methods together with a large sample set greatly increases the robustness of the findings.
One of the primary general findings in our study was that the mRNA expression level of a substantial number of genes in areas of genomic change is highly dependent on gene dosage. Although not unexpected, the present work is the first to show such a strong correlation at a global level in gliomas. To this end, it is important to note that any single outlier expression value that is far enough from the bulk value of the other samples will produce a correlation line to those other bulk data yielding an artificial correlation using our methods. Thus, we chose to remove the expression outliers from the correlation coefficient calculations in an attempt to reduce the number of false positives at the expense of possibly missing a few true positive correlations.
In our study, we chose expression probe set targets as the driving element of analysis, rather than genes themselves. The vast majority of genes on the Affymetrix microarrays are represented by several target sequences (probe sets), with expression greatly varying between them. Thus, by mapping every probe set to a group of SNPs, we found their correlation to be more accurate than if we combined expression levels of all probe sets for a single gene into a unique value. The accuracy of our methods was confirmed by the fact that most genes selected as having high correlation were represented well by a large percentage of their associated probe sets (Tables 1 and 2 ).
Applying the described methods, 1,297 genes with positive correlation and 42 genes with negative correlation were identified. Due to the large number of samples, the statistical significance obtained is very convincing (P < 10
À4
). Whereas a positive correlation between gene expression and copy number is easy to understand and points to genes that may be at the root of a genetic alteration, an explanation for genes with negative correlation (i.e., genes with up-regulated mRNA in areas of deletions or downregulated mRNA in areas of amplification) is less evident (Table 2 ; Fig. 2, bottom) . A clue to their relevance may be found in the observation that such genes are found in the areas of large CNA (most of them located on the frequently gained chromosomes 7 or the frequently lost chromosome 10), suggesting that negatively correlated genes may be a response to a passenger genomic alteration. In the case of genes showing negative correlation in areas of amplification, one possible explanation is that the gene in question may have a toxic or detrimental effect on tumor development and, therefore, might be down-regulated. This seems a plausible explanation for genes like EPHB6 (located in the amplified 7q34 region, near to MET), which is amplified in a number of gliomas but whose expression is down-regulated. This is consistent with the experimental observation that EPHB6 downregulation is important for an invasive tumor phenotype, whereas its overexpression has been correlated with a good prognosis in breast cancer (17) , melanoma (18) , and neuroblastoma (19) . Such genes, shown to be down-regulated in amplified chromosomal areas, are obviously very interesting candidates to evaluate as putative tumor suppressors. Conversely, in the case of negative correlation between copy number and expression in genes situated in deleted regions, one could speculate that these genes are vital for cell function, and thus a compensatory feedback loop may be responsible for expression levels above those expected from their gene dosage. The presence of CDC2 and vimentin in this gene list is consistent with such a model.
The Knudson hypothesis predicts that two successive mutations to an appropriate target gene (i.e., TSG), each to one allele, may be required for the inducing the full transforming phenotype. Thus, areas of LOH represent fertile regions for discovering potential new TSG because one allele of the gene of interest has, by definition, already been inactivated. Subsequent inactivation of the remaining allele can occur through transcriptional repression (via a number of mechanisms) or allelic mutation. Although gene expression platforms do generally detect genes functionally inactivated through DNA mutations (unless they effect mRNA stability and/or structure), one could potentially identify genes whose nondeleted alleles have been transcriptionally silenced using a gene expression microarray platform. Thus, we tested whether it was possible to detect genes in areas of LOH whose mRNA expression was substantially lower than what would have been predicted based on gene dosage (Fig. 3) . We identified 305 probe sets that met these criteria and were present in at least 10% of the tumor samples we evaluated. Several known TSGs were identified in this analysis (CDKN2B and PTEN) thereby validating the methodologic approach. We, however, additionally identified a number of very interesting new putative TSGs, such as CXCL12 (ligand to CXCR4, which is involved in chemoattraction and invasion) and HK1 (member of the hexokinase family, known to regulate apoptotic pathways). Visual inspection of the expression-copy number scatter plots for these genes shows that some of them segregate tumor samples into either very low or normal expressers (Fig. 3) . Validation of the expression levels by quantitative RT-PCR showed that these populations are real rather than an artifact, suggesting a potential epigenetic regulatory mechanism for the low expression.
The appearance of a substantial number of CpG islands at the 5 ¶ end of >80% of the genes identified with this method compared with 65% in a randomly selected set of genes suggests that our methods greatly enriched the sample set for epigenetically regulated genes. In support of this assertion, we show that two of the genes with the most clear bimodal expression level pattern (CXCL12 and PTER) had substantially higher promoter regionassociated CpG island methylation in the low-expressing glioma samples compared with the normal-expressing gliomas.
In summary, data from mRNA expression and DNA genotyping high-resolution arrays individually produce a wealth of molecular information, although the delineation of which events are primary to the biology of the tumor and which events are secondary or passenger events can be a daunting task. We have shown that integration of both array technologies potentially allows one to enrich for specific genes that might be involved in the initiation, propagation, and/or maintenance of the tumorigenic process. This and other similar analyses should make it easier to more accurately choose which genes to experimentally validate as potential new oncogenes or TSGs and, in so doing, increase the efficiency of identifying potential new targets for the treatment of gliomas and other tumors.
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